Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating on Black Diamond Therapeutics (NASDAQ: BDTX) and raised the price target from $13 to $14.